GSK has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) in ...
Investor's Business Daily on MSN
GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short
GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.
In a report released today, Benjamin Jackson CFA from Jefferies upgraded GlaxoSmithKline to a Buy, with a price target of £20.00. The company’s shares opened today at p1,631.50. Take advantage of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback